Drug-Radiotherapy Combinations in 2020 - A Landmark Year?

Amanda J. Walker; Theodore L. Deweese; Akila N. Viswanathan

doi:10.1001/jamaoncol.2020.6139

Drug-Radiotherapy Combinations in 2020 - A Landmark Year?

Amanda J. Walker, Theodore L. Deweese, Akila N. Viswanathan

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	349-350
Number of pages	2
Journal	JAMA Oncology
Volume	7
Issue number	3
DOIs	https://doi.org/10.1001/jamaoncol.2020.6139
State	Published - Mar 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2020.6139

Cite this

@article{a108d28021a046609e735867c73a5324,

title = "Drug-Radiotherapy Combinations in 2020 - A Landmark Year?",

author = "Walker, {Amanda J.} and Deweese, {Theodore L.} and Viswanathan, {Akila N.}",

note = "Funding Information: reported personal fees from AstraZeneca, Radimmune Therapeutics, RadioMedix Inc, and RefleXion outside the submitted work. Dr Viswanathan reported grants from National Cancer Institute outside the submitted work. No other disclosures were reported.",

year = "2021",

month = mar,

doi = "10.1001/jamaoncol.2020.6139",

language = "English (US)",

volume = "7",

pages = "349--350",

journal = "JAMA oncology",

issn = "2374-2437",